

Madrid, August 1, 2025

Pursuant to the provisions of Article 17 of Regulation (EU) No 596/2014 on market abuse and Article 227 of Law 6/2023 of 17 March 2023 on Securities Markets and Investment Services, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity ("**BME Growth**"), LABIANA HEALTH, S.A. (the "**Company**" or "**LABIANA**") communicates the following:

OTHER RELEVANT INFORMATION
Preliminary unaudited semester results

The Company presents an advance of the main figures of the **consolidated unaudited income statement** for the first half of 2025 of the LABIANA Group (in the process of review by the auditor AUREN AUDITORES SP, S.L.P.):

- **Turnover:** €39.2 million, representing growth of 12% compared to the same period last year.
- **Adjusted EBITDA (*):** €7.7 million, representing growth of 17% compared to the same period last year.

These figures show a continuation of the strong growth experienced by the Company in the previous financial year.

The Company hereby communicates to the Market the information and statements corresponding to the **unaudited financial results for the first half of 2025**. The company will publish the corresponding consolidated results report for the January-June 2025 period in October, as well as the limited review carried out by the auditors.


In accordance with the provisions of BME Growth Circular 3/2020, the information communicated herein has been prepared under the sole responsibility of the Company and its directors.

D. Manuel Ramos Ortega
CEO
LABIANA HEALTH, S.A.

Preliminary Results Report

January-June 2025

■ Net Turnover
■ Adjusted EBITDA*



* Earnings before interest and taxes after deducting the extraordinary expenses derived from the Miralta & Blantyre process, the divestment process in Serbia and the search for financing, as well as unaccrued invoices related to previous years.